Amy Goodrich
Impact in
- Genetics top 2%
- Chronic Lymphocytic Leukemia Research
-
- Lymphoma Diagnosis and Treatment
Papers in
- Genetics 7
- Chronic Lymphocytic Leukemia Research 7
-
- Hematopoietic Stem Cell Transplantation 2
- Co-authors
- Ian W. FlinnJohn C. ByrdMargaret S. LucasJamie K. WaselenkoMichael R. GreverJ. RosenbergMichael PearsonGeoffrey Ling
- Journals
- Clinical journal of oncology nursing (3 papers)Biology of Blood and Marrow Transplantation (2 papers)Journal of Clinical Oncology (1 paper)Frontiers in Immunology (1 paper)Cancer Treatment Reviews (1 paper)
- Partner nations
- United States
In The Last Decade
Amy Goodrich
14 papers receiving 543 citations
Peers
Comparison fields: 5 of 42
- Genetics 386
- Pathology and Forensic Medicine 397
- Immunology 206
- Hematology 82
- Oncology 151
Countries citing papers authored by Amy Goodrich
This map shows the geographic impact of Amy Goodrich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Goodrich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Goodrich more than expected).
Fields of papers citing papers by Amy Goodrich
This network shows the impact of papers produced by Amy Goodrich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Goodrich. The network helps show where Amy Goodrich may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Amy Goodrich, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 1 | |
| 2 | 2023 | 9 | |
| 3 | Evaluation of Clinical Pharmacy Services for Phase 1 Clinical Trials. | 2022 | 1 |
| 4 | 2021 | 3 | |
| 5 | 2017 | 2 | |
| 6 | 2009 | 11 | |
| 7 | 2008 | 9 | |
| 8 | 2007 | 21 | |
| 9 | 2007 | 2 | |
| 10 | 2006 | 9 | |
| 11 | 2003 | 2 | |
| 12 | 2001 | 411 | |
| 13 | 2000 | 79 | |
| 14 | Theophylline, pentostatin (Nipent), and chlorambucil: a dose-escalation study targeting intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disorders. | 2000 | 1 |
About Amy Goodrich
Amy Goodrich is a scholar working on Genetics, Hematology, Pathology and Forensic Medicine, Oncology and Statistics and Probability, having authored 14 papers that have together received 561 indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (7 papers), Lymphoma Diagnosis and Treatment (6 papers), Acute Lymphoblastic Leukemia research (2 papers), Immunodeficiency and Autoimmune Disorders (2 papers), Methemoglobinemia and Tumor Lysis Syndrome (2 papers), Hematopoietic Stem Cell Transplantation (2 papers), SARS-CoV-2 and COVID-19 Research (1 paper) and Neutropenia and Cancer Infections (1 paper). The work is most often cited by research in Genetics (386 citations), Pathology and Forensic Medicine (397 citations), Immunology (206 citations), Hematology (82 citations) and Oncology (151 citations). Amy Goodrich has collaborated with scholars based in United States. Frequent co-authors include Ian W. Flinn, John C. Byrd, Margaret S. Lucas, Jamie K. Waselenko, Michael R. Grever, J. Rosenberg, Michael Pearson, Geoffrey Ling, Timothy J. Murphy and Antonio J Grillo-López. Their work appears in journals such as Clinical journal of oncology nursing, Biology of Blood and Marrow Transplantation, Journal of Clinical Oncology, Frontiers in Immunology and Cancer Treatment Reviews.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.